BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28276897)

  • 1. Computational modeling of radiobiological effects in bone metastases for different radionuclides.
    Liberal FDCG; Tavares AAS; Tavares JMRS
    Int J Radiat Biol; 2017 Jun; 93(6):627-636. PubMed ID: 28276897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
    Guerra Liberal FD; Tavares AA; Tavares JM
    Med Phys; 2014 Nov; 41(11):114101. PubMed ID: 25370676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153.
    Guerra Liberal FDC; Tavares AAS; Tavares JMRS
    Appl Radiat Isot; 2016 Apr; 110():87-99. PubMed ID: 26773820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides.
    Sadremomtaz A; Masoumi M
    J Med Imaging Radiat Sci; 2019 Jun; 50(2):272-279. PubMed ID: 31176435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on the potential use of
    Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
    Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.
    Elgqvist J; Timmermand OV; Larsson E; Strand SE
    Anticancer Res; 2016 Jan; 36(1):103-9. PubMed ID: 26722033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets.
    Dant JT; Richardson RB; Nie LH
    Phys Med Biol; 2013 May; 58(10):3301-19. PubMed ID: 23615276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
    Handkiewicz-Junak D; Poeppel TD; Bodei L; Aktolun C; Ezziddin S; Giammarile F; Delgado-Bolton RC; Gabriel M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):846-859. PubMed ID: 29453701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (223)Ra and other bone-targeting radiopharmaceuticals-the translation of radiation biology into clinical practice.
    Turner PG; O'Sullivan JM
    Br J Radiol; 2015 Jun; 88(1050):20140752. PubMed ID: 25811095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical dosimetry in the treatment of bone tumors: old and new agents.
    Hindorf C; Flux GD; Ibisch C; Kraeber Bodéré F
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):198-204. PubMed ID: 21386790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concerning the health effects of internally deposited radionuclides.
    Raabe OG
    Health Phys; 2010 Mar; 98(3):515-36. PubMed ID: 20147792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the radiation absorbed dose produced by
    Azorín-Vega E; Rojas-Calderón E; Ferro-Flores G; Aranda-Lara L; Jiménez-Mancilla N; Nava-Cabrera MA
    Appl Radiat Isot; 2019 Apr; 146():66-71. PubMed ID: 30753987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An assessment of bone-seeking radionuclides for palliation of metastatic bone pain in a vertebral model.
    Sadremomtaz A; Masoumi M
    Ann Nucl Med; 2019 Apr; 33(4):252-264. PubMed ID: 30659480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Radiotherapy of Bone Metastases With Radionuclides.
    Murray I; Du Y
    Clin Oncol (R Coll Radiol); 2021 Feb; 33(2):98-105. PubMed ID: 33353771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model of metastatic growth valuable for radionuclide therapy.
    Bernhardt P; Ahlman H; Forssell-Aronsson E
    Med Phys; 2003 Dec; 30(12):3227-32. PubMed ID: 14713089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone-targeting radiopharmaceuticals including radium-223.
    Brady D; Parker CC; O'Sullivan JM
    Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of painful bone metastases with an emphasis on radionuclide therapy.
    Hillegonds DJ; Franklin S; Shelton DK; Vijayakumar S; Vijayakumar V
    J Natl Med Assoc; 2007 Jul; 99(7):785-94. PubMed ID: 17668645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new look at radionuclides therapy in metastatic disease of bone (review and prospects).
    Kim SI; Chen DC; Muggia FM
    Anticancer Res; 1988; 8(4):681-4. PubMed ID: 2460020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
    Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
    Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
    Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
    J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.